You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
康泰生物(300601.SZ)拉昇漲近8% 三季度淨利潤暴增303.21%
格隆匯 10-22 10:41
格隆匯10月22日丨康泰生物盤中拉昇一度漲7.75%至119.98元,市值824億元。公司昨晚公佈業績,2021年前三季度營收23.77億元,同比增67.37%;淨利潤10.36億元,同比增139.13%。其中,第三季度淨利潤7億元,同比增303.21%,主因新冠疫苗貢獻增量,同時乙肝疫苗恢復生產銷售。另外還值得注意的是,今年9月份,康泰生物的13價肺炎球菌多糖結合疫苗(破傷風類毒素/白喉類毒素)獲批上市,成為全球第三款、國內第二款13價肺炎疫苗。天風證券稱今年四季度有望開始貢獻業績,預計2022年13價肺炎疫苗增厚業績。其他產品管線也將陸續進入收穫期:1)人二倍體狂犬疫苗預計2021年四季度正式申報生產,有望2022年獲批;2)凍幹水痘疫苗已完成Ⅲ期臨牀試驗,預計有望2023年獲批;3)Sabin株脊髓灰質炎滅活疫苗(Vero細胞)Ⅲ期臨牀試驗中。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account